Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EU 307

Next Previous
X
Search
Drug Profile

EU 307

Alternative Names: EU-307; GPC3-IL18 CAR-T cell therapy-Eutilex

Latest Information Update: 22 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver cancer
  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 06 Sep 2023 Phase-I clinical trials in Liver cancer (Inoperable/Unresectable, Late-stage disease, Refractory metastatic disease) in Unknown (IV)
  • 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical studies in Liver cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 27 Mar 2023 Eutilex plans a phase I trial for Liver-cancer (Inoperable/Unresectable, Late-stage disease, Refractory metastatic disease) in April 2023 in unknown location(Parenteral, IV) (NCT05783570)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top